Litigation Details for PAR PHARMACEUTICAL, INC. v. LUITPOLD PHARMACEUTICALS, INC. (D.N.J. 2016)

PAR PHARMACEUTICAL, INC. v. LUITPOLD PHARMACEUTICALS, INC. (D.N.J. 2016)

Docket		Date Filed	2016-04-22
Court	District Court, D. New Jersey	Date Terminated	2017-10-31
Cause	35:271 Patent Infringement	Assigned To	William H. Walls
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	9,119,876; 9,295,657
Link to Docket	External link to docket

Details for PAR PHARMACEUTICAL, INC. v. LUITPOLD PHARMACEUTICALS, INC. (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-04-22				External link to document
2016-04-22	109		are two patents at issue in this case. The first patent, United States Patent No. 9,119,876 (the “‘…atse id, Ex. A. The second patent, Patent No. 9,295,657 (the “‘657 patent”), which is a continuation …infringement of their patents. Id. ¶1J 65—80. I. The Patents-in-S alt …infringes the Patents-in-Suit.” Id. The Complaint contains four counts of patent infringement…s ‘876 patent under 35 U.S.C. § 271(e)(2) and that Defendant will infringe the ‘876 patent under	External link to document

Litigation Summary and Analysis for PAR PHARMACEUTICAL, INC. v. LUITPOLD PHARMACEUTICALS, INC. (2:16-cv-02290)

Last updated: February 12, 2026

---

What are the key facts of the case?

PAR Pharmaceutical, Inc. filed a patent infringement lawsuit against Luitpold Pharmaceuticals, Inc. in the District of New Jersey. The dispute concerns the patent rights related to a pharmaceutical product or process. The case number is 2:16-cv-02290, filed in 2016.

The core allegations involve PAR asserting that Luitpold infringed on its patent rights by manufacturing or marketing a drug that violates its patent claims. Luitpold denied infringement and challenged the patent's validity.

What patents and claims are involved?

PAR asserted patents issued by the USPTO covering specific formulations or manufacturing processes. Although the precise patent numbers are not provided in the case summary, typically such cases involve method patents or composition patents related to drug delivery systems.

Key claims involved in the dispute include:

• Patent claims covering a specific formulation or process.
• Alleged infringement involving manufacturing or distribution of a generic or branded drug.

What procedural steps have occurred?

• Initial Complaint (2016): PAR files suit alleging patent infringement.
• Claim Construction: The court conducts Markman hearings to interpret key patent claims.
• Summary Judgment Motions: Parties likely filed motions to resolve patent validity or infringement pre-trial.
• Trial and Verdict: The case may have proceeded to a bench or jury trial, depending on court procedures.
• Appeals: Post-trial appeals possible if litigants dispute the verdict's validity or infringement ruling.

What are the notable legal issues?

1. Patent Validity: Whether the patents challenged are valid under patent law, including prior art considerations.
2. Infringement: Whether Luitpold's actions infringed on PAR's patent claims, based on claim interpretation.
3. Non-Infringement and Invalidity Defenses: Luitpold asserted defenses, possibly including inducement non-infringement or invalidity based on obviousness, anticipation, or prior disclosures.

What is the current status of the case?

As of the latest available data, the case appears not to have been resolved via a final judgment or settlement. Recent docket entries may show procedural motions or settlement discussions.

What implications does this case have?

• Patent enforcement: Emphasizes the importance of patent claim strength and clear claim construction.
• Generic drug entry: Such cases influence timing and strategy for generics seeking market entry.
• Legal precedents: Clarifies issues around patent validity defenses and infringement in the pharmaceutical sector.

What are the potential outcomes and consequences?

• Patent upheld and infringement found: Court may impose injunctive relief or damages.
• Patent invalidated or non-infringed: Luitpold could market the drug without patent constraints.
• Settlement: Parties may resolve the dispute through licensing or settlement agreements.

---

Key Takeaways

• The case involves patent rights associated with pharmaceutical formulations.
• Patent validity and claim interpretation are central.
• Litigation influences market competition, especially in branded and generic drug sectors.
• The outcome affects licensing, generics entry, and patent life strategies.

FAQs

1. What are the common defenses in patent infringement cases like this?
Defendants often argue that patents are invalid due to prior art, that their product does not infringe the patent claims, or that the patent claims are indefinite or overly broad.

2. How does patent litigation impact drug pricing and availability?
Successful infringement claims can delay generic entry, maintaining higher prices. Conversely, invalidation or settlement may expedite generic availability.

3. What role do patent claims play in the pharmaceutical industry?
Claims define the scope of patent rights, protecting specific formulations or processes that confer market exclusivity.

4. How long does a case like this typically last?
Patent litigation can last from 2 to 5 years, depending on complexity, procedural motions, and case volume.

5. Are there recent legal precedents set by similar cases?
Yes, courts have clarified issues like claim construction standardization and patent validity defenses, influencing subsequent pharmaceutical patent cases.

---

References

1. District of New Jersey Case Docket, 2:16-cv-02290.
2. US Patent and Trademark Office records.
3. Federal Circuit patent law precedents.